Difluprednate Ophthalmic Emulsion
Product Images NDC 43598-588

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Difluprednate Ophthalmic Emulsion (NDC 43598-588). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label (Bottle Label)

Bottle Label (Bottle Label)
This is a description of a pharmaceutical product named "Difluprednate Ophthalmic Emulsion 0.05%". It is manufactured and distributed by Dr. Reddy's Laboratories Inc. The product comes in a 5mL container and the recommended storage temperature is between 15°C and 25°C. The product should not be frozen and should be protected from light. There are some codes and numbers on the package, including the NDC code 43598-588-11, an expiration date, and a lot number. The recommended dosage can be found in the package insert.*
FDA Label Image

Carton Label (Carton Label)

Carton Label (Carton Label)
This is a description of a medication called Difluprednate Ophthalmic Emulsion used for topical ophthalmic use only. This medication is distributed by Dr. Reddy's Laboratories Inc. and is made in India. The medication comes in a 5mL bottle and the usual dosage can be found in the package insert. It is important to store this medication between 15°C to 25°C and to protect it from light. The medication contains active ingredient difluprednate 0.05% along with sorbic acid 0.1% as a preservative and other inactive ingredients such as boric acid, castor oil, glycerin, polysorbate 80, water for injection, sodium acetate anhydrous, edetate disodium dihydrate, sodium hydroxide to adjust the pH.*
FDA Label Image

Figure 1 (Figure1)

Figure 1 (Figure1)
This is a description of the percentage of subjects with anterior chamber cells clearing after taking Difluprednate ophthalmic emulsion 0.05% four times a day for 15 days. The results show that 100% of the subjects had their cell count reduced to zero. The study also compares the effect of the drug with a placebo, showing that the drug had a statistically significant effect (P<0.05).*
FDA Label Image

Figure 2 (Figure2)

Figure 2 (Figure2)
The data shows the percentage of subjects who were pain-free after receiving Difluprednate ophthalmic emulsion 0.05% QID compared to the placebo group on Day 3, Day 6, Day 15. The treatment group showed a statistically significant improvement in pain relief compared to the placebo group.*
FDA Label Image
Logo (Logo)
FDA Label Image

Structure (Structure)

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.